 |
|
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease
Peter Konyn, Aijaz Ahmed, Donghee Kim
Clin Mol Hepatol. 2023;29(Suppl):S43-S57. Published online 2022 Nov 22 DOI: https://doi.org/10.3350/cmh.2022.0351
|
|
Citations to this article as recorded by
 Secondary Growth Hormone Deficiency That Developed into Cirrhosis after Several Years of Interrupted Growth Hormone Replacement Therapy
Ayana Sueki, Daisuke Kaya, Shinsaku Nagamatsu, Chisa Yamamoto, Kohei Ohta, Yuya Matsuo, Yuya Nishio, Yusuke Komeda, Shoma Kikukawa, Kyohei Matsuura, Hideki Matsuo, Masakazu Uejima, Kei Moriya
Internal Medicine.2025; 64(3): 387. CrossRef Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study
Byungyoon Yun, Heejoo Park, Sang Hoon Ahn, Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon
American Journal of Gastroenterology.2025; 120(2): 410. CrossRef The Fibrosis-4 index predicts all-cause mortality in a cohort of patients at high cardiovascular risk partly through glomerular filtration rate reduction
Antonio Mirijello, Gabriella Pacilli, Antonio Siena, Antonio Mangiacotti, Maria Maddalena D'Errico, Daria Dilalla, Olga Lamacchia, Andrea Fontana, Massimiliano Copetti, Pamela Piscitelli, Giovanni Targher, Salvatore A. De Cosmo
Nutrition, Metabolism and Cardiovascular Diseases.2025; 35(1): 103768. CrossRef Secondhand Smoke Exposure and Metabolic Dysfunction-associated Steatotic Liver Disease in US Adolescents
Donghee Kim, Brandon J. Perumpail, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Aijaz Ahmed
Clinical Gastroenterology and Hepatology.2025; 23(4): 665. CrossRef Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply
Yewan Park, Jooyi Jung, Gi‐Ae Kim
Alimentary Pharmacology & Therapeutics.2025; 61(2): 400. CrossRef Red cell distribution width/platelet ratio predicts decompensation of metabolic dysfunction-associated steatotic liver disease-related compensated advanced chronic liver disease
Ming-Hua Zheng, Amedeo Lonardo
World Journal of Gastroenterology.2025;[Epub] CrossRef PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
Baokai Sun, Likun Zhuang
Clinical and Molecular Hepatology.2025; 31(1): e67. CrossRef Role of noninvasive tests on the prediction of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without cirrhosis: a systematic review and meta-analysis of aggregate and individual patient data
Nanicha Siriwong, Supachaya Sriphoosanaphan, Pakanat Decharatanachart, Tanat Yongpisarn, Stephen J. Kerr, Sombat Treeprasertsuk, Thodsawit Tiyarattanachai, Terapap Apiparakoon, Hannes Hagström, Camilla Akbari, Mattias Ekstedt, Terry Cheuk-Fung Yip, Grace
European Journal of Gastroenterology & Hepatology.2025; 37(3): 358. CrossRef Unmet needs of metabolic dysfunction – Associated “fatty or steatotic” liver disease
Yu-Ming Cheng, Shao-Wen Wang, Ching Wang, Chia-Chi Wang
Tzu Chi Medical Journal.2025;[Epub] CrossRef Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank
Tae Seop Lim, Sujin Kwon, Sung A. Bae, Hye Yeon Chon, Seol A. Jang, Ja Kyung Kim, Chul Sik Kim, Seok Won Park, Kyoung Min Kim
Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub] CrossRef Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management
Luigi Elio Adinolfi, Aldo Marrone, Luca Rinaldi, Riccardo Nevola, Antonio Izzi, Ferdinando Carlo Sasso
Exploration of Medicine.2025;[Epub] CrossRef The relationship between serum uric acid level and non-alcoholic fatty liver disease in northern China: a retrospective cohort study
Qian He, Xinyue Liu, Guoyong Ding, Yiying Wang, Xiaoting Luo, Wenyuan Cao, Weijia Xing
BMC Public Health.2025;[Epub] CrossRef Novel pyranopyridine derivatives and their radiolabeled nanoconjugates: An augmented approach for targeted cancer theranostics
Hesham A. Shamsel-Din, Mohamed M. Swidan, Ahmed B. Ibrahim, Mohamed A. Motaleb, Tamer M. Sakr
Journal of Drug Delivery Science and Technology.2025; 107: 106802. CrossRef Metabolic dysfunction-associated steatotic liver disease in adults
Daniel Q. Huang, Vincent W. S. Wong, Mary E. Rinella, Jerome Boursier, Jeffrey V. Lazarus, Hannele Yki-Järvinen, Rohit Loomba
Nature Reviews Disease Primers.2025;[Epub] CrossRef Elevated red blood cell folate levels are associated with metabolic dysfunction-associated steatotic liver disease: results from NHANES 2017–2020
Xin Liao, Song Yu, Lin Wang, Ruyue Zhang, Ke Yu
Frontiers in Physiology.2025;[Epub] CrossRef Cost‐effectiveness study of FIB‐4 followed by transient elastography screening strategy for advanced hepatic fibrosis in a NAFLD at‐risk population
Huiyul Park, Eileen L. Yoon, Mimi Kim, Sun‐Hong Kwon, Donghee Kim, Ramsey Cheung, Hye‐Lin Kim, Dae Won Jun
Liver International.2024; 44(4): 944. CrossRef Proposal of a Novel Serological Algorithm Combining FIB-4 and Serum M2BPGi for Advanced Fibrosis in Nonalcoholic Fatty Liver Disease
Sang Yi Moon, Yang Hyun Baek, Se Young Jang, Dae Won Jun, Ki Tae Yoon, Young Youn Cho, Hoon Gil Jo, Ae Jeong Jo
Gut and Liver.2024; 18(2): 283. CrossRef Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease
Richie Manikat, Aijaz Ahmed, Donghee Kim
Alimentary Pharmacology & Therapeutics.2024; 59(7): 893. CrossRef Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States
Donghee Kim, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
Alimentary Pharmacology & Therapeutics.2024; 60(1): 33. CrossRef Estimated pulse wave velocity in metabolic dysfunction‐associated steatotic liver disease and all‐cause/cause‐specific mortality
Donghee Kim, Richie Manikat, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
Journal of Gastroenterology and Hepatology.2024; 39(9): 1950. CrossRef Perspective article: determinants and assessment of cardiovascular risk in steatotic liver disease owing to metabolic dysfunction-addressing the challenge
Mohamad Jamalinia, Amedeo Lonardo
Metabolism and Target Organ Damage.2024;[Epub] CrossRef Accurate prediction of all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease using electronic health records
Ignat Drozdov, Benjamin Szubert, Ian A. Rowe, Timothy J. Kendall, Jonathan A. Fallowfield
Annals of Hepatology.2024; 29(5): 101528. CrossRef The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes‐related and cancer outcomes
David R. Riley, Theresa Hydes, Gema Hernadez, Sizheng S. Zhao, Uazman Alam, Daniel J. Cuthbertson
Liver International.2024; 44(10): 2538. CrossRef The Impact of Body Composition on the Prognosis of Nonalcoholic Fatty Liver Disease
Do Seon Song
Gut and Liver.2024; 18(4): 562. CrossRef Association of nonalcoholic fatty liver disease with new-onset atrial fibrillation stratified by age groups
Eun Ju Cho, Goh Eun Chung, Jeong-Ju Yoo, Yuri Cho, Kyu Na Lee, Dong Wook Shin, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Su Jong Yu
Cardiovascular Diabetology.2024;[Epub] CrossRef Metabolic Dysfunction-Associated Steatotic Liver Disease in Japan: Prevalence Trends and Clinical Background in the 10 Years before the Coronavirus Disease 2019 Pandemic
Akira Sato, Yumiko Oomori, Rika Nakano, Tomokazu Matsuura
Medicina.2024; 60(8): 1330. CrossRef Contemporary awareness of nonalcoholic fatty liver disease and viral hepatitis based on the stage
Donghee Kim, Richie Manikat, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
The American Journal of the Medical Sciences.2024; 368(6): 685. CrossRef High sensitivity troponins and mortality in the population with metabolic dysfunction-associated steatotic liver disease
Jingjing Hu, Yuteng Du, Yidan Zhou, Huiying Wang
Scientific Reports.2024;[Epub] CrossRef Impact of Korean Military Service on the Prevalence of Steatotic Liver Disease: A Longitudinal Study of Pre-enlistment and In-Service Health Check-Ups
Jaejun Lee, Jae Hyeop Jung, Sung Jun Choi, Beomman Ha, Hyun Yang, Pil Soo Sung, Si Hyun Bae, Jeong-A Yu
Gut and Liver.2024; 18(5): 888. CrossRef Vaccinium spp. Berries in the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease: A Comprehensive Update of Preclinical and Clinical Research
Ewelina Książek, Zuzanna Goluch, Marta Bochniak
Nutrients.2024; 16(17): 2940. CrossRef Metabolic bariatric surgery, alcohol misuse and liver cirrhosis: a narrative review
Matthew L. Basa, Danielle S. Cha, David P. Mitchell, Daniel L. Chan
Metabolism and Target Organ Damage.2024;[Epub] CrossRef Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
Yewan Park, Jooyi Jung, Seungbong Han, Gi‐Ae Kim
Alimentary Pharmacology & Therapeutics.2024; 60(11-12): 1599. CrossRef Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study
Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon, Hyung Ho Lee, Heejoo Park, Jian Lee, Youngsun Park, Byungyoon Yun, Jinsoo Chung
Cancers.2024; 16(18): 3161. CrossRef Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Prognosis of biopsy-confirmed metabolic dysfun
Yixuan Zhu, Xiaoyan Ma, Wenjing Ni, Yee Hui Yeo, Junping Shi, Jie Li
Clinical and Molecular Hepatology.2024; 30(4): 974. CrossRef Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality
Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
Clinical and Molecular Hepatology.2024; 30(4): 982. CrossRef Unraveling the Association of Liver Steatosis and Fibrosis with Vitamin B12: A Cross-Sectional Study
Silvia Espina, Diego Casas-Deza, Vanesa Bernal-Monterde, Ana Royo-Esteban, Maria Pilar García-Sobreviela, Pilar Calmarza, Ana B. Martinez-Martinez, Jesús Osada, Jose M. Arbones-Mainar
Metabolites.2024; 14(11): 618. CrossRef Association between Body Fat Distribution and Nonalcoholic Fatty Liver Disease/Fibrosis Based on Race/Ethnicity
Donghee Kim, George Cholankeril, Aijaz Ahmed
Journal of Obesity & Metabolic Syndrome.2024; 33(4): 326. CrossRef Nonlinear correlation between fatty liver index and carotid intima media thickness among individuals undergoing health examination
Yuanchen Zhou, Shaojie Duan, Rongrui Wang, Jialiang Chen, Shukun Yao
Frontiers in Endocrinology.2023;[Epub] CrossRef The growing burden of non-alcoholic fatty liver disease on mortality
Ju-Yeon Cho, Won Sohn
Clinical and Molecular Hepatology.2023; 29(2): 374. CrossRef Discovery of new pyridine heterocyclic hybrids; design, synthesis, dynamic simulations, and in vitro and in vivo breast cancer biological assays
Menna M. Abdelshaheed, Hussein I. El Subbagh, Mohamed A. Tantawy, Reem T. Attia, Khairia M. Youssef, Iten M. Fawzy
RSC Advances.2023; 13(23): 15689. CrossRef Synergistic Preventive Effect of Aerobic and Resistance Exercises on Nonalcoholic Fatty Liver Disease
Ju-Yeon Cho, Won Sohn
Gut and Liver.2023; 17(4): 487. CrossRef Comment on Clayton-Chubb et al. Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives. Nutrients 2023, 15, 687
Ludovico Abenavoli, Giuseppe La Torre, Natasa Milic
Nutrients.2023; 15(13): 2907. CrossRef Impact of Health Related QoL and Mediterranean Diet on Liver Fibrosis in Patients with NAFLD
Nuria Perez-Diaz-del-Campo, Gabriele Castelnuovo, Chiara Rosso, Aurora Nicolosi, Marta Guariglia, Eleonora Dileo, Angelo Armandi, Gian Paolo Caviglia, Elisabetta Bugianesi
Nutrients.2023; 15(13): 3018. CrossRef Aerobic and Resistance Exercise: Synergistic Influence for Nonalcoholic Fatty Liver Disease
Ho Soo Chun
Gut and Liver.2023; 17(4): 485. CrossRef From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
Ming-Lun Yeh, Ming-Lung Yu
Clinical and Molecular Hepatology.2023; 29(4): 969. CrossRef Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity
Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe
Clinical and Molecular Hepatology.2023; 29(4): 987. CrossRef Lifestyle of patients with non-alcoholic fatty liver disease: assessment of dietary habits and physical activity
T.S. Krolevets, M.I. Syrovenko, M.A. Livzan
Dokazatel'naya gastroenterologiya.2023; 12(4): 43. CrossRef Current epidemiology of chronic liver disease
Richie Manikat, Aijaz Ahmed, Donghee Kim
Gastroenterology Report.2023;[Epub] CrossRef
|